3000x650_AMP

Join us for a workshop



Enabling 5-minute PCR: Innovations in point-of-care testing

Wednesday, 15 November | 4:00 PM - 4:50 PM | Room 251BC

LEX Diagnostics have built upon core reagent systems provided by LGC Biosearch Technologies to develop an inhibitor tolerant reagent system. LEX believes point-of-care testing should provide high sensitivity tests that are easy to use and deliver clinically actionable results within a single visit to a health care provider. They have developed a rapid thermal cycling technology allowing gold standard sensitivity and specificity achievable through hydrolysis probe RT-PCR in a swab to result workflow. Learn how this technology eliminates the need for complex sample preparation and can efficiently amplify at groundbreaking speeds towards the realization of 5-minute PCR diagnostics.

Hear about:

  1. Decentralized testing for faster prognosis and treatment

  2. Developing reagent systems for extraction-free RT-PCR

  3. Assay design for rapid amplification by thermal cycling

  4. Developing a platform technology for a future assay menu

 

Add to calendar

AppleGoogleOffice 365OutlookOutlook.comYahoo


Meet the speaker

download (1)-1

Andrew Anyakwo

Head of Reagent Development, LEX Diagnostics

Bio

Andrew is the Head of Reagent Development at LEX Diagnostics. A clinical microbiologist by training with experience in working through the challenges posed by rapid molecular diagnostics. Andrew’s current drive is aiming high – for small-scale, affordable PCR testing that delivers reliable results in record time.

 
Tech Talks

Be the first to hear about innovation in the molecular diagnostics industry by stopping by booth #925 and #1024. While on-booth, you can speak with fellow experts or participate in one of our Tech Talks. These 5-minute talks will dive into specific technical discussions ranging from assay development and commercialisation to best practices in NGS assay implementation and use of reference materials for quality control.  

Biosearch Technologies

Day/Time

Thursday, 11/16, 4:00pm

Friday, 11/17, 9:30am

Friday, 11/17, 3:00pm

Saturday, 11/18, 9:30am

Title

Improving assay performance with oligo modifications

Quality considerations for enzymes for molecular diagnostic assay development

Benefits of partnering with oligo applications experts early in the assay development process

POC diagnostic testing and unique requirements - Sample input to answer output

Clinical Diagnostics

Day/Time

Thursday, 11/16, 4:30pm

Friday, 11/17, 9:45am

Friday, 11/17, 3:15pm

Title

Reference Materials for the Analytical Validation and Development of Tumor Informed MRD Assays with David Merriam, Ph.D.

Purpose Built Reference Materials for Methylated cfDNA with Andrew Anfora, Ph.D.

Benchmarking HRD Assays with Reference Materials with David Merriam, Ph.D.

image with organic shape for website-1

LGC Clinical Diagnostics at AMP 

LGC Clinical Diagnostics are global leaders in clinical genomic assay implementation and routine quality control. Our portfolio of Seraseq® somatic cancer products enables the promise of clinical genomics with the design and manufacture of patient-like reference materials for use in the development, validation, and implementation of molecular next-generation sequencing (NGS) assays that support clinical evaluation and management of cancer diseases. These clinically relevant reference materials cover the functional areas of:

o    Solid Tumor Profiling
o    Liquid Biopsy
o    Hematological Malignancy
o    Tumor Mutational Burden

6 tips for early-stage MDx companies seeking successful commercialisation

Many of the choices you make during the R&D phase can have a substantial impact on how successful you are in taking your molecular diagnostic assay to market. We share with you 6 tips for commercialisation. 

4400x983_AMP_footer
sbeadex™ Nucleic Acid Purification Technology
Minor groove binder (MGB) probes
Oligos for NGS and PCR